Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Market Cap	12.06B
Revenue (ttm)	5.98B
Net Income (ttm)	893.68M
Shares Out	n/a
EPS (ttm)	44.61
PE Ratio	13.50
Forward PE	n/a
Dividend	1.80 (0.30%)
Ex-Dividend Date	Sep 13, 2024

Volume	337,967
Average Volume	57,015
Open	605.00
Previous Close	605.55
Day's Range	545.05 - 619.65
52-Week Range	499.00 - 979.50
Beta	0.34
RSI	44.26
Earnings Date	May 20, 2025

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 1,687
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LINCOLN

Financial Performance

In 2023, Lincoln Pharmaceuticals's revenue was 5.81 billion, an increase of 13.76% compared to the previous year's 5.10 billion. Earnings were 933.05 million, an increase of 27.99%.